Eloxx Pharmaceuticals

Company Overview

Snapshot

Founded in September 2013, Eloxx Pharmaceuticals operates with 11–50 employees. The company has raised $98.5 million across 4 funding rounds from 10 investors. In April 2018, Eloxx Pharmaceuticals completed its initial public offering on NASDAQ.

Business overview

Eloxx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of compounds for rare genetic diseases. The company's core technology involves platform technologies designed to correct nonsense mutations and ribosomal mutations, which are implicated in various rare diseases and cancer. Eloxx Pharmaceuticals serves the healthcare and life sciences markets, specifically targeting patients with conditions such as cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, and Alport syndrome, operating within the pharmaceuticals and biotechnology sectors.

Strategic signal

In November 2024, Eloxx Pharmaceuticals announced promising results from its proof-of-concept trial for ELX-02, a treatment for Nonsense Mutation Alport Syndrome (NMAS). The trial demonstrated the production of collagen alpha 4 and alpha 5 proteins in patients, indicating a significant step forward in addressing this rare genetic disorder. This development signals strong progress in the company's clinical pipeline and validates its approach to genetic therapies, potentially leading to further advancements and milestone payments from partners like Almirall.

Company Intelligence Q&A

What was the outcome of the ELX-02 trial for Nonsense Mutation Alport Syndrome?

In November 2024, Eloxx Pharmaceuticals announced promising results from its proof-of-concept trial for ELX-02, a treatment for Nonsense Mutation Alport Syndrome (NMAS). The trial demonstrated the production of collagen alpha 4 and alpha 5 proteins in patients, marking a significant milestone in the therapy's development.

What recent financing and pipeline updates did Eloxx Pharmaceuticals provide?

In July 2024, Eloxx Pharmaceuticals announced it had dosed the first two subjects in a Phase 1 clinical trial of ZKN-013 for rare dermatological diseases and secured a binding commitment for an additional $3.2 million in financing. The company also received positive feedback from the FDA regarding its IND application for a Phase 2 clinical trial of ELX-02 in patients with NMAS.

What strategic partnership did Eloxx Pharmaceuticals enter into for ZKN-013?

In March 2024, Eloxx Pharmaceuticals and Almirall entered into an exclusive license agreement for the development and commercialization of ZKN-013 for rare dermatological diseases. Eloxx received an upfront payment of $3 million, with potential for up to $470 million in additional payments based on development, regulatory, and sales milestones.

What was the outcome of the Phase 2 clinical trial of ELX-02 for Alport Syndrome?

In November 2023, Eloxx Pharmaceuticals reported positive results from its Phase 2 clinical trial of ELX-02 for treating Alport Syndrome, showing significant improvement in kidney morphology and proteinuria in patients. These findings were presented at the American Society of Nephrology Kidney Week 2023.

What was the status of Eloxx Pharmaceuticals' Nasdaq listing in late 2023?

In December 2023, Eloxx Pharmaceuticals was highlighted in an article discussing delisted stocks, noting that the company had seen significant drops in equity value and was trading on the over-the-counter market. This followed an extension granted by Nasdaq in August 2023 to regain compliance with listing requirements.